Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junxian Yu

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Chemical Biology & Drug Design|November 12, 2025
Transformer-Based Model for Drug Design and Therapy Response PredictionZheng Gu, Junxian Yu
Annals of Palliative Medicine|May 28, 2021
Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literatureLing Li, Anqi Lou, Junxian Yu
Current Cancer Drug Targets|April 20, 2013
Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agentsJunxian Yu, Subhasree A Nag, Ruiwen Zhang
Epigenomics|June 6, 2026
Machine learning models predict the immunotherapy response in tumors on the basis of DNA methylationZheng Gu, Ning Jiang, Erle Deng, et al.
Disease Markers|September 5, 2022
The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled TrialsWei Chen, Ling Li, Sheng Cheng, et al.
The Clinical Respiratory Journal|April 2, 2024
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with KRAS mutations: A network meta-analysisLin Zhang, Wei Chen, Hongtao Wei, et al.
Bioscience, Biotechnology, and Biochemistry|January 1, 2020
Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapyYingjie Ma, Junxian Yu, Qin Li, et al.
BMC Cancer|August 23, 2023
Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50Wei Chen, Jiayi Chen, Lin Zhang, et al.
Journal of Inflammation Research|April 25, 2023
Immune-Related Colitis Induced by Camrelizumab: A Case ReportSheng Cheng, Yun Yang, Junxian Yu, et al.
Translational Cancer Research|March 12, 2026
Mature tertiary lymphoid structures tumor microenvironment-based risk model to assess patients with pancreatic ductal adenocarcinomaZheng Gu, Chaoran He, Sheng Cheng, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Chemical Biology & Drug Design|November 12, 2025
Transformer-Based Model for Drug Design and Therapy Response PredictionZheng Gu, Junxian Yu
Annals of Palliative Medicine|May 28, 2021
Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literatureLing Li, Anqi Lou, Junxian Yu
Current Cancer Drug Targets|April 20, 2013
Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agentsJunxian Yu, Subhasree A Nag, Ruiwen Zhang
Epigenomics|June 6, 2026
Machine learning models predict the immunotherapy response in tumors on the basis of DNA methylationZheng Gu, Ning Jiang, Erle Deng, et al.
Disease Markers|September 5, 2022
The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled TrialsWei Chen, Ling Li, Sheng Cheng, et al.
The Clinical Respiratory Journal|April 2, 2024
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with KRAS mutations: A network meta-analysisLin Zhang, Wei Chen, Hongtao Wei, et al.
Bioscience, Biotechnology, and Biochemistry|January 1, 2020
Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapyYingjie Ma, Junxian Yu, Qin Li, et al.
BMC Cancer|August 23, 2023
Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50Wei Chen, Jiayi Chen, Lin Zhang, et al.
Journal of Inflammation Research|April 25, 2023
Immune-Related Colitis Induced by Camrelizumab: A Case ReportSheng Cheng, Yun Yang, Junxian Yu, et al.
Translational Cancer Research|March 12, 2026
Mature tertiary lymphoid structures tumor microenvironment-based risk model to assess patients with pancreatic ductal adenocarcinomaZheng Gu, Chaoran He, Sheng Cheng, et al.
Pageof 4